Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. more
Time Frame | DNLI | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.71% | -2.27% | -0.57% |
1-Month Return | -22.48% | -3.96% | 1.21% |
3-Month Return | -25.35% | -9.7% | 7.57% |
6-Month Return | 3.84% | -3.37% | 11.45% |
1-Year Return | 6.59% | 3.71% | 28.48% |
3-Year Return | -49.72% | 3.8% | 29.52% |
5-Year Return | 21.53% | 39.78% | 90.66% |
10-Year Return | 7.09% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 26.68M | 335.66M | 48.66M | 108.46M | 330.53M | [{"date":"2019-12-31","value":7.95,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":14.5,"profit":true},{"date":"2022-12-31","value":32.31,"profit":true},{"date":"2023-12-31","value":98.47,"profit":true}] |
Cost of Revenue | 193.38M | 212.62M | 5.61M | 7.03M | 16.73M | [{"date":"2019-12-31","value":90.95,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":2.64,"profit":true},{"date":"2022-12-31","value":3.31,"profit":true},{"date":"2023-12-31","value":7.87,"profit":true}] |
Gross Profit | 26.68M | 335.66M | 48.66M | 101.43M | 313.81M | [{"date":"2019-12-31","value":7.95,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":14.5,"profit":true},{"date":"2022-12-31","value":30.22,"profit":true},{"date":"2023-12-31","value":93.49,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 100.00% | 93.52% | 94.94% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.52,"profit":true},{"date":"2023-12-31","value":94.94,"profit":true}] |
Operating Expenses | 239.86M | 272.94M | 344.41M | 449.21M | 527.23M | [{"date":"2019-12-31","value":45.49,"profit":true},{"date":"2020-12-31","value":51.77,"profit":true},{"date":"2021-12-31","value":65.32,"profit":true},{"date":"2022-12-31","value":85.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (213.18M) | 62.72M | (295.75M) | (340.74M) | (196.70M) | [{"date":"2019-12-31","value":-339.91,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-471.56,"profit":false},{"date":"2022-12-31","value":-543.3,"profit":false},{"date":"2023-12-31","value":-313.62,"profit":false}] |
Total Non-Operating Income/Expense | 30.44M | 18.48M | 9.19M | 29.55M | 96.54M | [{"date":"2019-12-31","value":31.53,"profit":true},{"date":"2020-12-31","value":19.14,"profit":true},{"date":"2021-12-31","value":9.52,"profit":true},{"date":"2022-12-31","value":30.61,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (197.97M) | 71.96M | (291.16M) | (325.97M) | (145.19M) | [{"date":"2019-12-31","value":-275.11,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-404.61,"profit":false},{"date":"2022-12-31","value":-452.99,"profit":false},{"date":"2023-12-31","value":-201.77,"profit":false}] |
Income Taxes | (351.00K) | 823.00K | (575.00K) | 21.00K | 30.00K | [{"date":"2019-12-31","value":-42.65,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-69.87,"profit":false},{"date":"2022-12-31","value":2.55,"profit":true},{"date":"2023-12-31","value":3.65,"profit":true}] |
Income After Taxes | (197.61M) | 71.14M | (290.58M) | (325.99M) | (145.22M) | [{"date":"2019-12-31","value":-277.8,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-408.49,"profit":false},{"date":"2022-12-31","value":-458.26,"profit":false},{"date":"2023-12-31","value":-204.15,"profit":false}] |
Income From Continuous Operations | (197.61M) | 72.78M | (290.58M) | (325.99M) | (124.43M) | [{"date":"2019-12-31","value":-271.51,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-399.25,"profit":false},{"date":"2022-12-31","value":-447.9,"profit":false},{"date":"2023-12-31","value":-170.96,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (197.61M) | 71.14M | (290.58M) | (325.99M) | (145.22M) | [{"date":"2019-12-31","value":-277.8,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-408.49,"profit":false},{"date":"2022-12-31","value":-458.26,"profit":false},{"date":"2023-12-31","value":-204.15,"profit":false}] |
EPS (Diluted) | (2.06) | 0.26 | (2.39) | (2.60) | (1.08) | [{"date":"2019-12-31","value":-792.31,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-919.23,"profit":false},{"date":"2022-12-31","value":-1000,"profit":false},{"date":"2023-12-31","value":-415.38,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
DNLI | |
---|---|
Cash Ratio | 9.61 |
Current Ratio | 9.98 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
DNLI | |
---|---|
ROA (LTM) | -23.81% |
ROE (LTM) | -35.09% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
DNLI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.09 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
DNLI | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 3339.01 |
P/B | 2.56 |
Price/FCF | NM |
EV/R | 2843.16 |
EV/Ebitda | NM |
Denali Therapeutics Inc (DNLI) share price today is $22.97
Yes, Indians can buy shares of Denali Therapeutics Inc (DNLI) on Vested. To buy Denali Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DNLI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Denali Therapeutics Inc (DNLI) via the Vested app. You can start investing in Denali Therapeutics Inc (DNLI) with a minimum investment of $1.
You can invest in shares of Denali Therapeutics Inc (DNLI) via Vested in three simple steps:
The 52-week high price of Denali Therapeutics Inc (DNLI) is $33.33. The 52-week low price of Denali Therapeutics Inc (DNLI) is $14.56.
The price-to-earnings (P/E) ratio of Denali Therapeutics Inc (DNLI) is
The price-to-book (P/B) ratio of Denali Therapeutics Inc (DNLI) is 2.56
The dividend yield of Denali Therapeutics Inc (DNLI) is 0.00%
The market capitalization of Denali Therapeutics Inc (DNLI) is $3.44B
The stock symbol (or ticker) of Denali Therapeutics Inc is DNLI